Authors' objectives: Marginal zone lymphoma is a type of cancer which usually develops very slowly. In people with marginal zone lymphoma, the body makes too many white blood cells called B-lymphocytes. These lymphocytes are abnormal and do not work properly and build up in different parts of the body such as the gut, salivary glands, eyes, spleen, and lymph nodes. Ibrutinib is a new type of drug for patients with marginal zone lymphoma given as a tablet once a day. Some studies have suggested ibrutinib may be helpful for people whose first treatment has failed and whose disease has spread. If ibrutinib is licensed for use in the UK, it could be a new treatment option for patients with marginal zone lymphoma that may reduce symptoms of the disease and increase survival.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/ibrutinib-imbruvica-for-relapsed-and-refractory-marginal-zone-lymphoma-second-or-subsequent-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Centre (NIHR HSC)